Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
NCT02560012 · The University of Texas Health Science Center, Houston · PHASE2 · terminated · last registry update 2018-10-12 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Loss of laboratory performing molecular analysis” | – | Registry record, The University of Texas Health Science Center, Houston |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CSF1R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-10-09Results posted on the registry: Daiichi Sankyo, PLX3397 + Temozolomide (NCT01790503)
- 2019-10-09Results posted on the registry: Daiichi Sankyo, PLX3397 + Pembrolizumab (NCT02452424)
- 2019-09-12Results posted on the registry: Dana-Farber Cancer Institute, Sunitinib + Regorafenib (NCT02164240)
- 2019-09-10Results posted on the registry: Incyte Corporation, Pembrolizumab + Epacadostat (NCT03260894)
- 2019-08-02Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Pazopanib (NCT01472081)
- 2019-05-31Results posted on the registry: Rutgers, The State University of New Jersey, therapeutic allogeneic lymphocytes + sunitinib malate (NCT00853125)
- 2019-04-25Results posted on the registry: University of Washington, Doxorubicin Hydrochloride + Ifosfamide (NCT01446809)
- 2019-04-10Phase 3 first posted: Amsterdam UMC, location VUmc, Sunitinib Malate + TAS 102 (NCT03909724)
- 2019-02-22Phase 3 first posted: Cure HHT, Pazopanib + Placebo oral capsule (NCT03850964)
- 2018-12-21Results posted on the registry: National Cancer Institute (NCI), Cabozantinib S-malate + Sunitinib Malate (NCT01835158)
- 2018-12-07Phase 3 first posted: Hoffmann-La Roche, Atezolizumab + Bevacizumab (NCT03768063)
- 2018-11-02Phase 3 first posted: Nektar Therapeutics, bempegaldesleukin + sunitinib (NCT03729245)
- 2018-10-16Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Ipilimumab (NCT02231749)
- 2018-10-03Results posted on the registry: Hoffmann-La Roche, Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody + Bevacizumab (NCT02420821)
- 2018-09-17Phase 3 first posted: Deciphera Pharmaceuticals, LLC, Ripretinib + Sunitinib (NCT03673501)
- 2018-07-19Phase 3 first posted: Xynomic Pharmaceuticals, Inc., Pazopanib + Abexinostat (NCT03592472)
- 2018-04-18Results posted on the registry: Medstar Health Research Institute, SU011248, Sutent (NCT00668811)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision